York, UK, 27th July 2016: ELRIG (European Laboratory Research & Innovation Group) announced today that two new Scientific Advisors have joined the committee to help organise the UK’s largest and most successful Drug Discovery conference, which will take place at ACC, Liverpool on 13th and 14th of October 2016.
“This is a very special year in that we are celebrating our 10 year anniversary of successfully running this meeting,” said Sanj Kumar, Chairman, ELRIG. “To ensure we continue to provide cutting edge scientific content to our 7,000 strong community we are honoured to welcome two new members to the Scientific Committee: Dr Chas Bountra, Professor of Translational Medicine, University of Oxford and Head of the Structural Genomic Consortium in Oxford, and Rachel Grimley, Director of Screening Sciences at AstraZeneca.”
Dr Del Trezise, Director and European Site Head, Essen Bioscience, and leader of the scientific committee, commented: “I am delighted to be working with both Rachel and Chas. They both bring a wealth of experience and contacts within the academic and drug discovery community which will ensure that we provide the best scientific content we can across the most cutting edge areas of early drug discovery.”
Drug Discovery is the UK’s leading conference and networking event for scientific researchers and business people involved in the science of drug discovery. ELRIG has hosted this event successfully in a variety of locations, but for this special 10th anniversary year, the event returns to a favourite venue at ACC in Liverpool.
“Del, Rachel and Chas are talented and knowledgeable leaders of the drug discovery industry,” said Dr Liz Quinn, Scientific Director of ELRIG. “Their experience and strong scientific credibility has allowed us to create a strong scientific programme that showcases innovative technologies and new emerging cellular approaches that can be used to overcome drug development challenges. Providing such breadth and depth of science will make DD16 an unmissable event for all drug discovery scientists and suppliers who wish to promote their latest technologies to this market place and network with colleagues across the industry.”
Drug Discovery 2016 is free to attend for delegates, and over the two day event ELRIG will host over 1,000 delegates, 50 speakers in the 6 track scientific programme, 100 exhibitors and a poster display. New to this year’s agenda there will also be a series of core technologies workshops and vendor tutorials. To register or for further information visit the ELRIG website at: http://elrig.org/portfolio/drug-discovery-2016/
